Avalon GloboCare Launches Online Sales of KetoAir Breathalyzer in the U.S. at Ketoair.us
July 18 2024 - 9:00AM
Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ:
ALBT), a developer of innovative cell-based technology,
cellular therapy and precision diagnostics, today announced the
official launch of online sales for the KetoAir™ breathalyzer
device and related accessories in the U.S. The products are now
available at www.ketoair.us.
KetoAir™ is a breathalyzer featuring Hot App
shareable technology with AI-enabled software, specifically
engineered for ketogenic health management (United States FDA
registration number: 3026284320). By leveraging the
nano-sensor-based technology and AI algorithms, the KetoAir™
breathalyzer is designed not only to assess the ketosis status of
its individual user but to also seamlessly record diet and exercise
details directly into the KetoAir™ app, accessible on both the
Apple App Store and Google Play Store.
The FDA-registered KetoAirTM breathalyzer
empowers users to take control of their health and wellness
journey. Utilizing advanced breath testing nano-technology, aligned
with the app's AI nutritionist, it offers personalized nutritional
and exercise recommendations tailored to individual health
goals.
“We're excited to launch online sales of
KetoAir™ breathalyzer in the U.S.,” stated David Jin, M.D., Ph.D.,
President and Chief Executive Officer of Avalon GloboCare. “We
believe the novel AI nutritionist feature sets a new standard in
the market, providing users with a holistic solution to monitor and
optimize their ketosis state and body fat burning rate. The 'Blow
to Know' technology is designed to provide precise and immediate
results with just a single exhale, allowing users to track how
different foods and activities affect their ketone levels. Avalon
has exclusive distributorship rights for the KetoAir™ breathalyzer
in North America, South America, EU, and the UK, and will continue
to work on the launch of its KetoAir™ breathalyzer sales in the
remainder of these territories.”
To celebrate the launch, Avalon is offering a
special introductory price of $199 (regular retail price $249). Use
coupon code 'intro20' at checkout to receive a 20% discount.
For questions and inquiries about the KetoAir
Breathalyzer, please contact the customer service team at
support@ketoair.us.
Calling all Keto Coaches! Please contact the
sales team at sales@ketoair.us to discuss partnership
programs.Follow KetoAir™ on social media:
Instagram: @ketoair_qaFacebook:
@KetoAirQATikTok: @ketoair_qa
About Avalon GloboCare Corp.
Avalon GloboCare Corp. (NASDAQ: ALBT) is a
commercial stage company dedicated to developing and delivering
innovative, transformative, precision diagnostics and clinical
laboratory services. Avalon is working to establish a leading role
in the innovation of diagnostic testing, utilizing proprietary
technology to deliver precise, genetics-driven results. The Company
also provides laboratory services, offering a broad portfolio of
diagnostic tests, including drug testing, toxicology, and a broad
array of test services, from general bloodwork to anatomic
pathology, and urine toxicology. For more information about Avalon
GloboCare, please visit www.avalon-globocare.com.
For the latest updates on Avalon GloboCare’s
developments, please follow our twitter at @avalongc_avco
Forward-Looking Statements
Certain statements contained in this press
release are “forward-looking statements” within the meaning of the
federal securities laws. Forward-looking statements are made based
on our expectations and beliefs concerning future events impacting
the Company and therefore involve several risks and uncertainties.
You can identify these statements by the fact that they use words
such as “will”, “anticipate”, “estimate”, “expect”, “should”,
“may”, and other words and terms of similar meaning or use of
future dates, however, the absence of these words or similar
expressions does not mean that a statement is not forward-looking.
Forward-looking statements provide current expectations of future
events based on certain assumptions and include any statement that
does not directly relate to any historical or current fact,
including statements regarding the ability to enter into a
definitive agreement, as well as the Company’s commercialization,
distribution and sales of KetoAir and the product’s ability to
compete with other testing methods for determining ketosis. Actual
results may differ materially from those indicated by such
forward-looking statements as a result of various important factors
as disclosed in our filings with the Securities and Exchange
Commission located at their website (http://www.sec.gov), including
our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and
Form 8-Ks filed or furnished with the SEC. In addition to these
factors, actual future performance, outcomes, and results may
differ materially because of more general factors including
(without limitation) general industry and market conditions and
growth rates, economic conditions, and governmental and public
policy changes. The forward-looking statements included in this
press release represent the Company's views as of the date of this
press release and these views could change. However, while the
Company may elect to update these forward-looking statements at
some point in the future, the Company specifically disclaims any
obligation to do so. These forward-looking statements should not be
relied upon as representing the Company's views as of any date
subsequent to the date of the press release.
Contact Information: Avalon GloboCare Corp.4400
Route 9, Suite 3100Freehold, NJ 07728PR@Avalon-GloboCare.com
Investor Relations:Crescendo Communications, LLCTel: (212)
671-1020 Ext. 304albt@crescendo-ir.com
Avalon GloboCare (NASDAQ:ALBT)
Historical Stock Chart
From Sep 2024 to Oct 2024
Avalon GloboCare (NASDAQ:ALBT)
Historical Stock Chart
From Oct 2023 to Oct 2024